Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
about
Mechanisms of drug resistance: daptomycin resistancePrevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitisEvaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection.Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infectionAttenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitisShort-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanismsClinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Staphylococcus aureus gene expression in a rat model of infective endocarditis.Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens.Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approachIn vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates.Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype.Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus.Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureusAdjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis.Combinatory antibiotic therapy increases rate of bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus spinal implant infectionTelavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.Correlation of cell membrane lipid profiles with daptomycin resistance in methicillin-resistant Staphylococcus aureus.Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.Prescribing trends with daptomycin (cubicin) for the treatment of gram-positive infectionsVancomycin-rifampin combination therapy has enhanced efficacy against an experimental Staphylococcus aureus prosthetic joint infection.Rifampin combination therapy for nonmycobacterial infections.Treatment strategies for infective endocarditis.The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms.Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy.Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.Daptomycin plus fosfomycin, a synergistic combination in experimental implant-associated osteomyelitis due to methicillin-resistant Staphylococcus aureus in rats.New in vitro and in vivo models to evaluate antibiotic efficacy in Staphylococcus aureus prosthetic vascular graft infection.Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains.
P2860
Q26779944-87AFC95B-B438-462B-93D1-DBA8940DFCE7Q28757559-6674137F-E0F2-4CA0-B817-66C191014F43Q33239640-3045D69A-ED8E-41E9-A8CE-D4092C5F5D37Q33622963-9A96A955-C158-4055-8DDC-767400C0EBF4Q33676211-C0A37A5A-0C76-46DB-9D03-D8F54D7C019BQ33883648-AA6E34E0-4E49-486E-99B6-377ED3495DC4Q34045273-D4597B2C-4D14-46C9-A731-9D23F529CF16Q34045376-45E96372-138B-4EDF-89C1-74818362A791Q34157657-96489A22-AB00-4046-B120-B1557FDA8000Q34491802-7C19896C-AE16-4F0E-88CC-2176BA2BF862Q34721715-5139FF5C-DD21-4A19-A581-E7F9B71C466AQ35026595-E4774707-4448-4921-BDA6-85894BCE7144Q35096905-E3E60F16-457A-41EF-94BF-27BE3E718681Q35191555-19BC0D52-8E4E-468E-9CDB-8142C65056E7Q35746096-1A8533F6-CD3F-478C-8A98-5F05D6DD2868Q35771368-3F718B06-E725-4247-B636-095F11CC739AQ35806369-7E6B2D4C-B4B1-4A9A-AD7B-FCBB78AB2B82Q35879100-E7771FC8-BFA7-4FDF-B147-59452D25836CQ36171566-464D328D-00FA-4872-9BBF-36E1EBCD3123Q36292752-7FB6D4B7-0071-4373-A230-726EE3DC8AEEQ36364106-FB2688CF-4B7E-43AE-9989-65D0C4517668Q36396117-B85C9B25-BECE-4609-BBDB-B5730EB7AEA4Q36422686-B6910B61-DA09-4BC7-9D35-9478FDBDC656Q36558432-83A3716A-5E0A-4D81-9516-75910D771D02Q36565462-42AF9BA9-DC6F-4A7E-9A4C-CF80BC31DBEEQ36744825-80DCBC18-8048-4861-A1D1-36DB6FA2458EQ36903680-52FCC9C1-BB52-4E85-BA26-28E3A25AAF4CQ37195896-E9536784-49DF-4EAB-B5AE-E39153972C6BQ37263918-608D74AF-A485-42D7-99D6-A20945207336Q37672039-F5E91644-4D86-4BE9-804F-7283B7560795Q37681564-22A2F4D3-41E6-4E8A-842A-B332D2AA5BFAQ37954711-13D40435-2C0D-47A3-83E3-2CDB28D25F22Q38232494-26642AA9-3FC5-43F6-BD15-929BAE954115Q38725968-822DFA9D-8505-492B-947D-DDFA1A7A2AF7Q38892614-75E31A43-8FB9-4FB7-A672-5EC95D144084Q39182290-3CD25E85-56AE-4A65-AA88-6F7242E52F25Q40018152-3AD6385A-82E8-4760-85D8-3D54C5827ECDQ40189196-3CBF8E66-359C-46AC-A89D-7B7B12A80FFCQ40362524-E99EF4D9-3891-4BE8-84BC-6446415827D2Q40441728-8B6A8392-25AE-42E5-97CB-EB1BDCD9C2AD
P2860
Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Efficacy of daptomycin in expe ...... sistant Staphylococcus aureus.
@en
Efficacy of daptomycin in expe ...... sistant Staphylococcus aureus.
@nl
type
label
Efficacy of daptomycin in expe ...... sistant Staphylococcus aureus.
@en
Efficacy of daptomycin in expe ...... sistant Staphylococcus aureus.
@nl
prefLabel
Efficacy of daptomycin in expe ...... sistant Staphylococcus aureus.
@en
Efficacy of daptomycin in expe ...... sistant Staphylococcus aureus.
@nl
P2093
P2860
P1476
Efficacy of daptomycin in expe ...... sistant Staphylococcus aureus.
@en
P2093
Claudie Thauvin Eliopoulos
George M Eliopoulos
George Sakoulas
Jeff Alder
P2860
P304
P356
10.1128/AAC.47.5.1714-1718.2003
P407
P577
2003-05-01T00:00:00Z